Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
15 evidence topics · 6 sources
Complete estrogen receptor antagonist and selective estrogen receptor degrader
“Palazestrant (OP-1250) is a novel oral, complete estrogen receptor antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both transcriptional activation function domains, AF1 and AF2, required for the estradiol-generated transcriptional activity of ER” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Blockade of AF1 and AF2 compared with selective estrogen receptor modulators
“Selective estrogen receptor modulators (SERMs) block only the AF2 domain, leaving the AF1 domain active and capable of gene transcription. Palazestrant is a complete ER antagonist (CERAN) and selective ER degrader (SERD) that acts by blocking both AF1 and AF2 domains to completely block ER-driven transcriptional activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rationale for blocking both activation functions
Inhibition of AF1-dependent activity in uterine cells
“Elacestrant demonstrated partial agonist activity, with maximum response of 24%; imlunestrant, fulvestrant, and OP-1250 did not induce measurable AP activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“imlunestrant, fulvestrant, and OP-1250 completely inhibited activity with IC50 values of 32, 9.4, and 6.4 nmol/L, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Estrogen receptor degradation in breast cancer cells
“OP-1250 degrades ERα with comparable potency to fulvestrant (DC50 0.52 nmol/L and 0.56 nmol/L, respectively; Emax 62% and 69%, respectively)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OP-1250 treatment reduced ERα protein levels by 63% relative to vehicle in MCF7 and 72% in CAMA-1 cells” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Proteasome-dependent degradation
“In MCF7 cells, degradation of ERα by OP-1250 was observed as early as 2 hours after treatment, levels reduced in a time-dependent manner, and degradation was blocked by treatment with the proteasome inhibitor MG-132” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antagonism of residual receptor after degradation
“Palazestrant promotes ER degradation at levels similar to that of fulvestrant and greater than that of elacestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, the presence of residual ER protein has been detected in vitro with these treatments” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, palazestrant demonstrates robust CERAN activity that completely blocks ER-induced transcription, ensuring full inhibition of any residually available ER remaining from its SERD activity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Receptor selectivity
“OP-1250 demonstrated no agonist-like cross-reactivity on glucocorticoid, progesterone, or androgen receptors. Inhibition of agonist-induced androgen receptor transcriptional activity was detected only at >1 μmol/L OP-1250” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Activity against ESR1 Y537S and D538G mutant receptors
“In AP assays conducted with mutant Ishikawa cells, OP-1250 displayed favorable potency against both mutants, comparable to that of fulvestrant” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both AP and proliferation assays, CERANs showed reduced potency in the mutant cell lines relative to wild-type.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Antiproliferative potency in estrogen-stimulated cells
Corepressor NCoR1 recruitment
Earlier hypothesis for AF1 inhibition
“While the mechanism of AF1 inhibition by CERANs such as OP-1250 has not been determined, we hypothesize that this may occur through recruitment of ER corepressor proteins such as NCoR, as suggested previously” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote